期刊文献+

肿瘤相关慢性炎症性贫血和肿瘤相关缺铁性贫血红细胞相关参数及铁代谢指标的比较

Comparison of red blood cell and iron metabolism parameters between cancer related anemia of chronic disease and cancer related anemia of iron deficiency
原文传递
导出
摘要 目的:分析与比较肿瘤相关慢性炎症性贫血(CRA-ACD)和肿瘤相关缺铁性贫血(CRA-IDA)红细胞相关参数及铁代谢指标,以明确两种贫血的临床特征并探讨红细胞相关参数及铁代谢指标在两者鉴别诊断中的意义。方法:选取初治确诊14例CRA-IDA及16例CRA-ACD患儿进行红细胞参数[平均红细胞容积(MCV)、平均红细胞血红蛋白量(MCH)、平均红细胞血红蛋白浓度(MCHC)]和铁代谢指标[血清铁(SI)、总铁结合力(TIBC)、转铁蛋白饱和度(TS)与血清铁蛋白(SF)]检测,并与20例同期健康对照组比较,对结果进行统计学分析。结果:两个研究组MCV[CRA-IDA组(77.53±6.78)fL,CRA-ACD组(80.12±4.83)fL]均小于对照组(90.01±2.90)fL],差异均有统计学意义(P<0.01);且CRA-IDA组小于CRA-ACD组,差异有统计学意义(P<0.05)。两个研究组的MCH、MCHC、SI、TS及TIBC均低于对照组,差异有统计学意义(P<0.01)。两个研究组SF含量均高于对照组,差异有统计学意义(P<0.01);组间比较差异无统计学意义(P>0.05)。两组MCV、SI、TS及TIBC异常率均相当,差异无统计学意义(P>0.05)。CRA-IDA组有7例、CRA-ACD组有11例SF高于200μg/L,差异有统计学意义(P<0.05);CRA-ACD组全部高于30μg/L,而CRA-IDA组仅5例低于30μg/L,差异无统计学意义(P>0.05)。结论:本研究CRA-IDA和CRA-ACD的红细胞参数(MCV下降)及常规铁代谢指标(SI、TS和TIBC下降,SF升高)相似,故不能简单地采用上述指标对CRA进行病因分析,需寻找新的生物学指标更好地鉴别CRA-IDA和CRA-ACD。 Objective:To analyze and compare the parameters of red blood cell(RBC)and iron metabolism in the children with cancer related anemia of chronic disease(CRA-ACD)and cancer related iron-deficiency anemia(CRA-IDA),in order to make clear the features of two kinds of anemia and the significance of the parameters of iron metabolisms and RBC in the differential diagnosis.Methods:A total of 14 cases of CRA-IDA and 16 cases of CRA-ACD were selected,and another 20 healthy children were enrolled into the control group.The RBC parameters(MCV,MCH,and MCHC)and iron metabolism parameters(SI,TIBC,TS,and SF)were detected and compared between the three groups.Results:MCV in CRA-IDA group([77.53±6.78]fL)and CRA-ACD group([80.12±4.83]fL)was smaller than that in control group([90.01±2.90]fL)(P<0.01).MCH,MCHC,SI,TS,and TIBC in CRA-IDA group and CRA-ACD group were lower than in control group(P<0.01).SF in CRA-IDA group and CRA-ACD group was higher than that in control group(P<0.01),but the above parameters showed no significance difference between CRA-IDA group and CRA-ACD group(P>0.05).The abnormal rates of MCV,SI,TS,and TIBC were similar in the two groups(P>0.05).SF value of 7 cases in CRA-IDA group and 11 cases in CRA-ACD group were higher than 200μg/L(P<0.05).None of the CRA-ACD group had an SF level lower than 30μg/L,and only 5 cases of CRA-IDA group were found with low SF level(P>0.05).Conclusion:The clinical manifestations of CRA-IDA and CRA-ACD are similar in this study.Red blood cell parameters such as MCV,SI,TS,and TIBC could not be simply used to analyze the etiology of CRA,and novel biological indicators should be found to identify the CRA-IDA and CRA-ACD.
作者 吐地古丽·吐尔逊 赵阿兰 武贝 詹晓芸 谭沛 芦映红 黄娟 Tudiguli Tuerxun;ZHAO Alan;WU Bei;ZHAN Xiaoyun;TAN Pei;LU Yinghong;HUANG Juan(Wuhan University of Science and Technology School of Medicine,Wuhan 430081,Hubei,China;Dept.of Pediatric Hematology,Maternal and Child Hospital of Hubei Province,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430070,Hubei,China)
出处 《武汉大学学报(医学版)》 CAS 2023年第4期463-467,共5页 Medical Journal of Wuhan University
基金 武汉市卫生与计划生育委员会资助项目(编号:[2014]41号)。
关键词 肿瘤相关性贫血 缺铁性贫血 红细胞相关参数 铁代谢 Cancer Related Anemia Iron Deficiency Anemia Red Blood Cell Parameters Iron Metabolism
  • 相关文献

参考文献6

二级参考文献41

  • 1魏志武,李锋春.对2286例患者输血前4项检验结果的流行病学研究[J].职业与健康,2004,20(7):63-65. 被引量:12
  • 2叶任高.内科学[M]6版.北京:人民卫生出版,2007.86-90.
  • 3National Comprehensive Cancer Network. NCCN clinical practiceguidelines in oncology: cancer and chemotherapy-induced anemia.2011, V. 2 [EB/OL]. (2011-08-01). http://www. nccn. org/index. asp.
  • 4Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-celllung cancer: role of erythropoietin in the management of anemia[J].Ann Oncol, 1999,10 (Suppl 5): 91-94.
  • 5Ludwig H, Van Belle S, Barrett-Lee P, et al. The European CancerAnaemia Survey (ECAS): A large, multinational, prospective surveydefining the prevalence; incidence, and treatment of anaemia in cancerpatients [J]. EurJ Cancer, 2004,40: 2293-2306.
  • 6Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietinresponse in patients with the anemia of cancer[j]. N EngJ Med, 1990,322: 1689-1692.
  • 7Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical,biologic, and molecular aspects[J].J Natl Cancer Inst, 2001, 93: 266-276.
  • 8Ludwig H, Fritz E. Anemia in cancer patients [J]. Semin Oncol,1998,25 (3 Suppl 7):2-6.
  • 9Leyland-Jones B, Semiglazov V,Pawlicki M, et al. Maintaining normalhemoglobin levels with epoetin alfa in mainly nonanemic patients withmetastatic breast cancer receiving first-line chemotherapy: A survivalstudy[J].J Clin Oncol, 2005,23(25): 5960-5972.
  • 10Bohlius J, Schmidlin K, Brillant C, et al. Recombinant humanerythropoiesis-stimulating agents and mortality in patients with cancer:a meta-analysis of randomised trials [J]. Lancet, 2009,373: 1532-1542.

共引文献226

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部